D

Global Pharmaceutical Contract Manufacturing Market Research Report 2023-2030: Burgeoning Opportunities with Patent Expiration and Increasing Adoption of 505(B)(2) Pathway of Small Molecules Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 14, 2023
Pharmaceutical, Health, Other Manufacturing, Manufacturing, Pressure, Research, D, CDMO, Government, PCM, FDF, CMOS, Infection, Therapy, PLI, Capacity, CMO, Growth, Active ingredient, API, Patent, Fine chemical, Pharmaceutical industry

Pharmaceutical contract manufacturing (PCM) global market is expected to grow at a mid single digit CAGR from 2023 to 2030 to reach $100,102.8 million by 2030.

Key Points: 
  • Pharmaceutical contract manufacturing (PCM) global market is expected to grow at a mid single digit CAGR from 2023 to 2030 to reach $100,102.8 million by 2030.
  • This trend is favoring contract manufacturing service providers and is expected to increase the share in the pharmaceutical manufacturing market.
  • Contract pharmaceutical manufacturing services are mainly focused on the manufacturing of Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF).
  • The factors such as increased trend of outsourcing and high uptake of small molecules drugs across diverse therapeutics are driving the pharmaceutical contract manufacturing global market.

Colle McVoy Lands High-Profile Chief Creative Officer Ciro Sarmiento

Retrieved on: 
Tuesday, November 14, 2023
Public Relations, Investor Relations, Marketing, Advertising, Communications, Digital Marketing, Lynx, GSK plc, D, Creativity, PepsiCo, Character, Anheuser-Busch, DirecTV, Coca-Cola, Multimedia, Growth, MillerCoors, Frito-Lay, AT&T, The One Show, Management, Effie Kapsalis, Unilever, Mars, Tide

Minneapolis-based creative agency Colle McVoy has hired award-winning creative executive Ciro Sarmiento as its new chief creative officer.

Key Points: 
  • Minneapolis-based creative agency Colle McVoy has hired award-winning creative executive Ciro Sarmiento as its new chief creative officer.
  • Sarmiento joins the agency effective today, following creative leadership roles at several shops in New York.
  • View the full release here: https://www.businesswire.com/news/home/20231114114473/en/
    “This is a pivotal moment for our agency, and we’re proud to have Ciro join our leadership team during this time of growth,” said Christine Fruechte, chief executive officer, Colle McVoy.
  • Sarmiento also serves as a coach for Creative LIAisons, a program designed as a global initiative to develop, educate, inspire and nurture emerging creative talent.

Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, November 13, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Webcast, Interest, Plasma kallikrein, Safety, D, Therapy, First Nations Summit, IND, Investment, PD, Experiment, Patient, Allergy, Journal, Atopic dermatitis, Hereditary angioedema, Investigational New Drug, HAE, Half-life, YTE, OX40, Pharmacodynamics, ACAAI, Pharmaceutical industry, Cryptocurrency, Asteria, Pharmacology

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • We now expect to deliver initial proof-of-concept results in Q1 2024 from the Phase 1b/2 ALPHA-STAR trial in HAE patients.
  • STAR-0215 achieved potentially therapeutic levels in less than one day and showed an estimated half-life of up to 127 days.
  • Additional preclinical results were shared in the Journal of Pharmacology and Experimental Therapeutics that support STAR-0215’s potential as a best-in-class plasma kallikrein inhibitor.

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Other Science, Science, Safety, D, Pharmaceutical industry in Switzerland, Therapy, TED, IND, Investment, Patient, Neonatal Fc receptor, LDL, Conditional sentence, Pharmacokinetics, Half-life, Immunoglobulin G, Intravenous therapy, Pharmaceutical industry, Management, Viridian

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the third quarter ended September 30, 2023.

Key Points: 
  • Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the third quarter ended September 30, 2023.
  • The ongoing THRIVE Phase 3 clinical trial of VRDN-001 in patients with active TED continues to enroll patients with topline results expected in mid-2024.
  • Net Loss: The company’s net loss was $47.7 million for the third quarter of 2023, compared with $28.9 million for the same period last year.
  • Viridian will not be hosting a conference call to discuss its third quarter financial results.

RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Tuesday, November 14, 2023
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Principal, Pancreatic cancer, Associate, Research, Safety, Tomorrow's India Global Summit, D, Data monitoring committee, FSVM, Insurance, Patient, CIO, ASX, LAPC, IMU, Standard of care, Cancer, Florida International University, Symposium, Partnership, Imugene, Immunotherapy, Horizon, TAMP, Clinical, Medical imaging, Payment card, Medicine

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the third quarter ended September 30, 2023.
  • Financial Highlights for Third Quarter ended September 30, 2023:
    Cash Position: Cash and cash equivalents as of September 30, 2023, were $3.2 million.
  • R&D Expenses: Research and development expenses were $1.6 million for the quarter ended September 30, 2023, compared to $0.8 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $1.4 million for the quarter ended September 30, 2023, compared to net loss of $2.1 million for the quarter ended September 30, 2022.

Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
Stem Cells, Biotechnology, Pharmaceutical, Optical, Oncology, Health, Health Technology, Clinical Trials, Webcast, RPE, Interest, B2M, Research, VAC, D, Therapy, Visual acuity, OCT, IND, Lineage Cell Therapeutics, Eterna, INL, Patient, FDA, Collaboration, G&A, OPL, Expense, Investigational New Drug, NYSE American, Trial of the century, ELM, AMD, Geographic atrophy, Roche, Survival, Partnership, Congress, Letter, TASE, NK, Pharmaceutical industry, Fine chemical, Vaccine, Genentech

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
  • “The Lineage team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs, supporting our alliances and working to establish new collaborations,” stated Brian M. Culley, Lineage CEO.
  • Interested parties may access today’s conference call and webcast, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.
  • A live webcast of the conference call will be available online in the Investors section of Lineage’s website.

Grove Announces Fiscal Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Retail, Home Goods, Webcast, DTC, Carbon, EBITDA, P&L, PVA, D, Polyvinyl alcohol, Enchantment, International, Stock, Collection, Kroger, History, Public expenditure, Research, HEB, Root, Advertising, Adjustment, Wellness, Abies balsamea, CVS, App Store (iOS/iPadOS), Grove Collaborative, SKU, Walmart, VIP, Health, PVOH, Video game, Bookkeeping, Online shopping, Risk management, Internet service provider, Meijer, Amazon, Kaph, Wegmans, Target

Grove Brand products, including our owned Grove Co.™, Peach Not Plastic™, and Rooted Beauty® brands, represented 44.8% of net revenue in the third quarter of 2023, down 20 basis points quarter over quarter and 210 basis points year-over-year.

Key Points: 
  • Grove Brand products, including our owned Grove Co.™, Peach Not Plastic™, and Rooted Beauty® brands, represented 44.8% of net revenue in the third quarter of 2023, down 20 basis points quarter over quarter and 210 basis points year-over-year.
  • DTC Net Revenue Per Order was $65.2 in the third quarter of 2023, a record for Grove, up 0.7% quarter-over-quarter and up 7.6% year-over-year.
  • Excluding this product category, Grove Brands plastic intensity is 0.63 in the third quarter of 2023, in line with the second quarter of 2023 and the third quarter of 2022.
  • However, due to our refined fourth quarter advertising strategy, we are slightly reducing our revenue guidance for 2023,” stated Sergio Cervantes, Chief Financial Officer of Grove Collaborative.

Dain Leaders Provides a Lively Practice Environment with 'HAIO', a VR Medical Education Contents

Retrieved on: 
Thursday, December 14, 2023
Hand, D, Government, Learning, Student, Voice recognition, Ecosystem, COVID-19, CPR, University, VR, Hospital, HMD, Environment, Tutoring, Nursing

Having provided learner-oriented education environment and unique learning contents utilizing VR contents since 2020, Dain Leaders signed license partner agreements for metaverse platform with Unity Korea and Unity Starter Editor.

Key Points: 
  • Having provided learner-oriented education environment and unique learning contents utilizing VR contents since 2020, Dain Leaders signed license partner agreements for metaverse platform with Unity Korea and Unity Starter Editor.
  • This way, Dain Leaders presents a new type of learning model of the future by providing VR/AR contents to the education/public sectors in Korea and establishing a contents creation ecosystem with learner and teacher participants.
  • Dain Leader's major product, 'HAIO (Hospital All In One)' is a VR solution with voice recognition and hand tracking technologies tailored for contactless practice training at the medical and nursing colleges after the outbreak of COVID-19.
  • Currently, Dain Leaders mainly runs the hand-tracking-based VR contents for medical training and the motion-recognition-based AR mobile contents as its core business.

Westfield Specialty Names 2 Leaders; Enters International Property D&F Business

Retrieved on: 
Thursday, December 14, 2023
Syndicate, Acquisition, D, International, Hiscox, 1301, London and Lancashire Insurance, International Insurance Company, Catlin Group, Kalara International Properties, Lloyd's of London, Richard Catlin, Financial services

WESTFIELD CENTER, Ohio, Dec. 14, 2023 /PRNewswire/ -- Westfield Specialty is forming a team to lead its entry into international property direct and facultative (D&F) insurance.

Key Points: 
  • WESTFIELD CENTER, Ohio, Dec. 14, 2023 /PRNewswire/ -- Westfield Specialty is forming a team to lead its entry into international property direct and facultative (D&F) insurance.
  • The new International Property division will be led by Richard Wood, Executive Vice President, Head of Property, International Insurance, who will join the company in July 2024.
  • Richard Wood joins Westfield Specialty from Lancashire Group, where he was Group Head of D&F Property.
  • "As we continue to diversify our overall portfolio, we now have an increasingly appealing offering to serve needs in the international property D&F market," says Westfield Specialty President Jack Kuhn.

Westfield Specialty Names 2 Leaders; Enters International Property D&F Business

Retrieved on: 
Thursday, December 14, 2023
Syndicate, Acquisition, D, International, Hiscox, 1301, London and Lancashire Insurance, International Insurance Company, Catlin Group, Kalara International Properties, Lloyd's of London, Richard Catlin, Financial services

WESTFIELD CENTER, Ohio, Dec. 14, 2023 /PRNewswire/ -- Westfield Specialty is forming a team to lead its entry into international property direct and facultative (D&F) insurance.

Key Points: 
  • WESTFIELD CENTER, Ohio, Dec. 14, 2023 /PRNewswire/ -- Westfield Specialty is forming a team to lead its entry into international property direct and facultative (D&F) insurance.
  • The new International Property division will be led by Richard Wood, Executive Vice President, Head of Property, International Insurance, who will join the company in July 2024.
  • Richard Wood joins Westfield Specialty from Lancashire Group, where he was Group Head of D&F Property.
  • "As we continue to diversify our overall portfolio, we now have an increasingly appealing offering to serve needs in the international property D&F market," says Westfield Specialty President Jack Kuhn.